FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A.
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx ...
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy ...
A new study led by researchers at Baylor College of Medicine found that the use of a take-home electrical stimulation device improved muscle perfusion, the rate at which oxygen is delivered to muscles ...
• Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. • TAMP enables localized, targeted delivery of CF33 to ...
RenovoRx, Inc (RNXT). (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath ®, a novel, FDA-cleared delivery ...
Therapeutic hypothermia of donors didn't preserve kidney function as well as machine perfusion of the organ during cold storage, a randomized trial found. Compared with kidneys pumped with a ...
First commercially available cell culture solution for HEK293 cells and perfusion -– optimized for high cell density (HCD), intensified processes and perfusion cultures Additional capabilities for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results